GlassScriptPhysician profile
Sarah J Rosen
NPI 1740345883
$786.92
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2020: $93.18 · 2021: $185 · 2022: $180.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.84 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $82.70 | 2021-2022 | |
| Covidien LP | $54.65 | 2019 | |
| Exeltis, USA INC. | $54.60 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $54.59 | 2019-2020 | |
| Avion Pharmaceuticals | $41.74 | 2020-2022 | |
| Allergan, INC. | $39.53 | 2019 | |
| Organon LLC | $30.18 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $29.43 | 2022 | |
| Merck Sharp & Dohme LLC | $27.14 | 2020-2022 | |
| Therapeuticsmd, INC. | $24.61 | 2019-2020 | |
| Myovant Sciences INC. | $17.38 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.96 | 2021 | |
| Hologic Sales and Service, LLC | $16.35 | 2019 | |
| Agile Therapeutics, INC. | $14.68 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $14.39 | 2019 | |
| Duchesnay USA Incorporated | $14.33 | 2019 | |
| Millicent US INC | $11.82 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Rosen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.